Exploring the Potential of Gemcitabine-metal-organic Frameworks in Combating Pancreatic Cancer Under Ketogenic Conditions

Overview

Journal BMC Cancer

Publisher Biomed Central

Date 2025 Jan 9

PMID 39789481

Authors

Samira Nekoufar

Marjan Ghorbani

Sahar Safaei

Gholamreza Alinezhadi Khosroushahi

Farzad Izak Shirian

Behzad Baradaran

Masoumeh Tavakoli-Yaraki

Affiliations

Soon will be listed here.

Abstract

Background: Inadequate treatment responses, chemotherapy resistance, significant heterogeneity, and lengthy treatment durations create an urgent need for new pancreatic cancer therapies. This study aims to investigate the effectiveness of gemcitabine-loaded nanoparticles enclosed in an organo-metallic framework under ketogenic conditions in inhibiting the growth of MIA-PaCa-2 cells.

Methods: Gemcitabine was encapsulated in Metal-organic frameworks (MOFs) and its morphology and size distribution were examined using transmission electron microscopy (TEM) and Dynamic light scattering (DLS) with further characterization including FTIR analysis. Various drug groups were established to evaluate their influences on cell cytotoxicity, apoptosis rate, cell cycle distribution, levels of superoxide dismutase (SOD), glutathione peroxidase (GPx), malondialdehyde (MDA), and cell migration.

Results: The gemcitabine-MOF was thoroughly analyzed to determine its size, morphology, and chemical composition, confirming its successful preparation. The treatment results showed an increase in the number of apoptotic cells following gemcitabine-MOF treatment, which was found to be associated with cell cycle arrest in the sub-G1 phase. Moreover, these treatments also resulted in reduced cell migration, decreased activity of antioxidant enzymes (SOD, GPx), and increased accumulation of MDA. Additionally, when exposed to ketogenic conditions (where beta-hydroxybutyrate is present in a glucose-limited medium), there was a further increase in cell cycle arrest, accompanied by a more pronounced decrease in SOD and GPx activity, as well as decreased migration.

Conclusion: The use of metal-organic framework to encapsulate gemcitabine yielded notable pro-apoptotic effects in MIA-PaCa-2 cells with which ketogenic conditions had a synergistic effect that can hold promise for improving therapeutic options.

References

Okusaka T, Furuse J . Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020; 55(4):369-382. PMC: 7080663. DOI: 10.1007/s00535-020-01666-y. View

Xiong L, Liu S, Liu C, Guo T, Huang Z, Li L . The protective effects of melatonin in high glucose environment by alleviating autophagy and apoptosis on primary cortical neurons. Mol Cell Biochem. 2022; 478(7):1415-1425. PMC: 10209297. DOI: 10.1007/s11010-022-04596-w. View

Thummuri D, Khan S, Underwood P, Zhang P, Wiegand J, Zhang X . Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X-Specific Degrader DT2216. Mol Cancer Ther. 2021; 21(1):184-192. PMC: 8742767. DOI: 10.1158/1535-7163.MCT-21-0474. View

Austin M, Kuo E, Van Den Eeden S, Mandelson M, Brentnall T, Kamineni A . Family history of diabetes and pancreatic cancer as risk factors for pancreatic cancer: the PACIFIC study. Cancer Epidemiol Biomarkers Prev. 2013; 22(10):1913-7. PMC: 3808252. DOI: 10.1158/1055-9965.EPI-13-0518. View

Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F . Role of gemcitabine in cancer therapy. Future Oncol. 2006; 1(1):7-17. DOI: 10.1517/14796694.1.1.7. View

Glew R . You can get there from here: acetone, anionic ketones and even-carbon fatty acids can provide substrates for gluconeogenesis. Niger J Physiol Sci. 2012; 25(1):2-4. View

Buijs A, Poot M, van der Crabben S, Van Der Zwaag B, van Binsbergen E, van Roosmalen M . Elucidation of a novel pathogenomic mechanism using genome-wide long mate-pair sequencing of a congenital t(16;21) in a series of three RUNX1-mutated FPD/AML pedigrees. Leukemia. 2012; 26(9):2151-4. DOI: 10.1038/leu.2012.79. View

Zhang Y, Li Y . β-hydroxybutyrate inhibits malignant phenotypes of prostate cancer cells through β-hydroxybutyrylation of indoleacetamide-N-methyltransferase. Cancer Cell Int. 2024; 24(1):121. PMC: 10981303. DOI: 10.1186/s12935-024-03277-6. View

Zu Nurain Ahmad S, Salleh W, Yusof N, Yusop M, Hamdan R, Ismail A . Efficiency of magnetic zeolitic imidazolate framework-8 (ZIF-8) modified graphene oxide for lead adsorption. Environ Sci Pollut Res Int. 2024; . DOI: 10.1007/s11356-024-33322-w. View

10.

Poff A, Ari C, Arnold P, Seyfried T, DAgostino D . Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer. 2014; 135(7):1711-20. PMC: 4235292. DOI: 10.1002/ijc.28809. View

11.

Crake R, Gasmi I, Dehaye J, Lardinois F, Peiffer R, Maloujahmoum N . Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells. 2023; 12(10). PMC: 10217245. DOI: 10.3390/cells12101414. View

12.

Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R, Gandhi V . Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22(4 Suppl 11):3-10. View

13.

Woolf E, Syed N, Scheck A . Tumor Metabolism, the Ketogenic Diet and β-Hydroxybutyrate: Novel Approaches to Adjuvant Brain Tumor Therapy. Front Mol Neurosci. 2016; 9:122. PMC: 5110522. DOI: 10.3389/fnmol.2016.00122. View

14.

Birhanu G, Javar H, Seyedjafari E, Zandi-Karimi A . Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomed Pharmacother. 2017; 88:635-643. DOI: 10.1016/j.biopha.2017.01.071. View

15.

Jiang S, Wang R, Zhang X, Wu F, Li S, Yuan Y . Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non-small cell lung cancer and via the epithelial-to-mesenchymal transition process. Oncol Lett. 2020; 20(1):346-356. PMC: 7291674. DOI: 10.3892/ol.2020.11536. View

16.

Zhang Y, Lu X, Zhang Y, Zhao D, Gong H, Du Y . The Effect of Extracellular Superoxide Dismutase (SOD3) Gene in Lung Cancer. Front Oncol. 2022; 12:722646. PMC: 8959130. DOI: 10.3389/fonc.2022.722646. View

17.

Wang N, Li Y, He F, Liu S, Liu Y, Peng J . Assembly of Celastrol to Zeolitic Imidazolate Framework-8 by Coordination as a Novel Drug Delivery Strategy for Cancer Therapy. Pharmaceuticals (Basel). 2022; 15(9). PMC: 9504028. DOI: 10.3390/ph15091076. View

18.

Yarahmadi S, Abdolvahabi Z, Hesari Z, Tavakoli-Yaraki M, Yousefi Z, Seiri P . Inhibition of sirtuin 1 deacetylase by miR-211-5p provides a mechanism for the induction of cell death in breast cancer cells. Gene. 2019; 711:143939. DOI: 10.1016/j.gene.2019.06.029. View

19.

Rawla P, Sunkara T, Gaduputi V . Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1):10-27. PMC: 6396775. DOI: 10.14740/wjon1166. View

20.

Bartmann C, Janaki Raman S, Floter J, Schulze A, Bahlke K, Willingstorfer J . Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation. Cancer Metab. 2018; 6:8. PMC: 5996481. DOI: 10.1186/s40170-018-0180-9. View